| Son10) (2013) | 1) VAS2) PPT Score at CV17 | 1) Significant Decrease of VAS* 2) Significant Increase of PPT Score* |
| Shim8) (2012) | 1) VAS | Significant Decrease of VAS* |
| Yu15) (2023) | 1) TER2) VAS | 1) TER 62.50%2) Significant Decrease of VAS* |
| Gao16) (2020) | 1) TER2) The symptom relief time | 1) T>C* [T : 100.0% / C : 68.2%]2) T<C* [T : 3.533±1.502)d / C : (5.409±1.501)d] |
| Xie17) (2019) | 1) TER2) VAS3) The recovery of tongue papilla， tongue coating， salivary secretion and estrogen level | 1) T>C† [T : 93.7% / C : 49.2%]2) Significant Decrease of Pain in VAS after 3week*, 6week† and 3month† / Significant Decrease of Pain in VAS after 6week* ① 3weeks after treatment : T<C† [6.55±0.57*/ 8.75±0.49] ② 6weeks after treatment : T<C† [1.57±0.32* / 7.83±0.46*] ③ After 3months : T<C† [1.79±0.53* / 8.29±0.54]3) Scores of treatment group more significantly decrease than control group* ① T<C* [80.8% / 32.1%] ② T<C* [85.5% / 34.2%] ③ T<C* [78.6% / 34.1%] |
| Wan18) (2019) | 1) TER2) VAS | 1) T>C* [T : 50.0% / C : 40.0%]2) T<C* [T : 4.2±1.5* / C : 6.2±1.1] |
| Xiong19) (2018) | 1) TER2) VAS3) TCM symptom scores4) TDL survival quality5) The incidence of adverse reactions | 1) T>C* [T : 96.36% / C : 76.36%]2) T<C* [T : 2.52±1.41* / C : 4.02±1.63*]3) T<C* [T : 7.58±1.83* / C : 12.57±2.85*]4) T>C* [T : 78.45±5.92* / C : 68.95±6.84*]5) T<C* [T : 1.82% / C : 14.55%] |
| Hou20) (2020) | 1) TER2) VAS | 1) T>C* [T : 87.5% / C : 62.5%]2) T<C* [T : 1.68±0.28* / C : 2.78±0.30*] |
| Zhang21) (2018) | TER | 95.00% |
| Liu22) (2017) | 1) TER2) HAMA Anxiety Scale Score3) 5-HT, E2, LH, FSH | 1) T>C* [T : 55.00% / C : 45.00%]2) T<C* [T : 4.42±1.38* / C : 9.52±4.57]3) T>C* ① 5-HT : [T : 160.19±30.08* / C : 115.27±48.67] ② E2 : [T : 38.52±17.28* / C : 20.12±8.46]T<C (P>0.05) ③ LH : [T : 39.37±17.48 / C : 78.56±37.32] ④ FSH : [T : 37.74±14.86 / C : 47.65±20.31] |
| Zhang23) (2020) | 1) TER2) VAS3) TCM symptome scores4) IL-6, TNF-α | 1) T>C* [T : 92.59% / C : 70.37%]2) T<C‡ [T : 2.18±1.24‡ / C : 4.50±1.37‡]3) T<C (P=0.001) [T : 8.37±1.94‡ / C : 10.31±2.15‡]4) T<C‡ ① IL-6 : [T : 132.63±8.96‡ / C : 175.93±11.47‡] ② TNF-α : [T : 41.31±5.59‡ / C : 72.23±4.35‡] |
| Ge24) (2020) | VAS | 1) After 1month G3<G1* G3<G2* [G1 : 2.75±1.07* / G2 : 2.97±1.04* / G3 : 2.29±0.65*]2) After 3months G3<G2* [G1 : 3.99±1.27 / G2 : 4.28±1.06 / G3 : 3.84±1.12*] |
| Yang25) (2017) | TER | 97.2% |
| Chen26) (2004) | TER | 85.29% |
| Zhou27) (2012) | 1) TER2) VAS | 1) T>C† [T : 77.27% / C : 40%]2) T<C† [T : 3.32±0.63†/ C : VAS 8.24±0.64†] |
| Yang28) (2011) | TER | 90.90% |
| Zhou29) (2009) | TER | T>C* [T : 90.6% / C : 60%] |
| Peng30) (2019) | TER | 1) After 4weeks T>C* [T : 82.86% / C : 64.0%]2) After 12weeks T>C* [T : 74.29% / C : 44.0%] |
| Hu31) (2016) | TER | 1) After 2weeks T>C (P>0.05) [T : 75% / C : 58.3%]2) After 4weeks T>C* [T : 89.6% / C : 66.7%] |
| Zhao14) (2012) | TER | TG>CG (P>0.05) [TG : 82.5% / CG : 76.7%] |
| Li32) (2011) | 1) TER2) VAS | 1) T>C* [T : 93.75% / C : 71.87%]2) T<C* [T : 2.08±0.37 / C : 3.28±0.54] |
| Guo33) (2009) | 1) TER | 86.25% |
| Huang34) (2007) | TER | T>C* [T : 80% / C : 47.5%] |
| Lou35) (2023) | 1) VAS2) symptom checklist 90 (SCL-90)3) The level of β-endorphin in plasma | 1) T<C (P=0.306) [T : 2.75±1.07‡ / C : 2.97±1.04‡]2) T<C (P>0.05) ① Somatization [T : 1.47±0.08* / C : 1.48±0.06] ② Obsessive compulsive [T : 1.36±0.05 / C : 1.43±0.04] ③ Interpersonal senstivity [T : 1.17±0.03 / C : 1.21±0.03] ④ Depression [T : 1.17±0.02 / C : 1.20±0.02] ⑤ Anxiety [T : 1.29±0.03 / C : 1.28±0.03] ⑥ Hostility [T : 1.12±0.02 / C : 1.14±0.03] ⑦ Phobic anxiety [T : 1.09±0.02* / C : 1.12±0.02] ⑧ Paranoid ideation [T : 1.12±0.02 / C : 1.14±0.03] ⑨ Psychoticism [T : 1.08±0.02 / C : 1.11±0.01] ⑩ Others (diet and sleep) [T : 1.48±0.06* / C : 1.47±0.06] ⑪ Number of positive items [T : 17.30±1.96 / C : 19.62±1.66] ⑫ Total [T : 112.20±2.67 / C : 114.40±2.32]3) T>C (P>0.05) [T : 8.60±5.48* / C : 8.31±0.40] |
| Zhao36) (2020) | TER | G1 TER 85.18% / G2 TER 82.47% |
| Wang37) (2015) | 1) TER2) VAS | 1) 85.0%2) Significant Increase of PPT Score† |
| Sun38) (2011) | VAS | 1) After 1month T<C* [T : 3.900±0.994† / C : 4.500±0.707†]2) After 3months T<C* [T : 1.800±0.789 / C : 3.000±0.667†] |